Search alternatives:
burden increased » use increased (Expand Search), care increased (Expand Search)
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
Showing 121 - 140 results of 24,273 for search '(( significantly ((lower decrease) OR (larger decrease)) ) OR ( significant burden increased ))', query time: 0.60s Refine Results
  1. 121
    The increasing burden of pancreatic cancer in Brazil from 2000 to 2019: estimates from the Global Burden of Disease Study 2019.

    The increasing burden of pancreatic cancer in Brazil from 2000 to 2019: estimates from the Global Burden of Disease Study 2019. by Diogo Oliveira Chaves (12698033)

    Published 2022
    “…<div><p>Abstract INTRODUCTION: Pancreatic cancer is increasing worldwide. The burden of pancreatic cancer in Brazil and its states was analyzed and compared with that from the USA and China. …”
    Save to List
    Saved in:
  2. 122
    A small local advancement index (LAI) increases metastatic burden.

    A small local advancement index (LAI) increases metastatic burden. by Kimiyo N. Yamamoto (213724)

    Published 2019
    Save to List
    Saved in:
  3. 123
    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in the N-deficient treatment.

    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in... by Ranjeeta Adhikari (9905958)

    Published 2023
    Save to List
    Saved in:
  4. 124
    Trends in the burden of stroke attributed to smoking.

    Trends in the burden of stroke attributed to smoking. by Jaber S. Alqahtani (8822396)

    Published 2025
    Save to List
    Saved in:
  5. 125
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 126
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 127
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 128
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 129
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 130
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 131
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 132
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 133
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 134
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 135
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 136
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 137
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 138
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 139
    No significant differences in Aβ plaque burden between dCA1 and vCA1 in APP/PS1 mice.

    No significant differences in Aβ plaque burden between dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

    Published 2024
    Save to List
    Saved in:
  20. 140
    Trend of TI values with age: The TI values decreased significantly with the increase of age, * p<0.01 vs other groups.

    Trend of TI values with age: The TI values decreased significantly with the increase of age, * p<0.01 vs other groups. by Yunmeng Da (707943)

    Published 2024
    Save to List
    Saved in:

Search Tools: